Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: Performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices

American Journal of Gastroenterology

Volumn 103, Issue 1, 2008, Pages 162-169

  Langhorst, Jost ^a   Elsenbruch, Sigrid ^b   Koelzer, Julia ^a   Rueffer, Andreas ^c   Michalsen, Andreas ^a   Dobos, Gustav J ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c Labor L+S AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; LACTOFERRIN; LEUKOCYTE ELASTASE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE MARKER; ENDOSCOPY; ENTERITIS; FECES ANALYSIS; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SERUM; SEX RATIO; STATISTICAL ANALYSIS; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; ENDOSCOPY, GASTROINTESTINAL; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LACTOFERRIN; LEUKOCYTE ELASTASE; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 37849053698     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01556.x     Document Type: Article

References (51)

1. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: Useful, magic, or unnecessary toys? Gut 2006 55 : 426 31.
2. Crama-Bohbouth G, Pena AS, Biemond I, et al. Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease? Gut 1989 30 : 1236 40.
3. Mazlam MZ, Hodgson HJ. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut 1992 33 : 773 8.
4. Niederau C, Backmerhoff F, Schumacher B, et al. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Hepatogastroenterology 1997 44 : 90 107.
5. Bitton A, Peppercorn M, Antonioli D, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001 120 : 13 20.
6. Linskens R, van Bodegraven A, Schoorl M, et al. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig Dis Sci 2001 46 : 644 8.
7. Moran A, Jones A, Asquith P. Laboratory markers of colonoscopic activity in ulcerative colitis and Crohn's colitis. Scand J Gastroenterol 1995 30 : 356 60.
8. Schunk K, Kern A, Oberholzer K, et al. Hydo-MRI in Crohn's disease: Appraisal of disease acvtivity. Invest Radiol 2000 35 : 431 7.
9. Gomes P, du Boulay C, Smith C, et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986 27 : 92 5.
10. Solem CA, Loftus EV, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005 11 : 707 12.
11. Levay PF, Viljoen M. Lactoferrin: A general review. Haematologica 1995 80 : 252 67.
12. Baveye S, Elass E, Mazurier J, et al. Lactoferrin: A multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin Chem Lab Med 1999 37 : 281 6.
13. Guerrant RL, Araujo V, Soares E, et al. Measurement of fecal lactoferrin as a marker of fecal leukocytes. J Clin Microbiol 1992 30 : 1238 42.
14. Kayazawa M, Saitoh O, Kojima K, et al. Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: Comparison with other neutrophil-derived proteins. Am J Gastroenterol 2002 97 : 360 9.
15. Frosch M, Metze D, Foell D, et al. Early activation of cutaneous vessels and epithelial cells is characteristic of acute systemic onset juvenile idiopathic arthritis. Exp Dermatol 2005 14 : 259 65.
16. Foell D, Frosch M, Sorg C, et al. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta 2004 344 : 37 51.
17. Poullis A, Foster R, Northfield TC, et al. Review article: Faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther 2002 16 : 675 81.
18. Voganatsi A, Panyutich A, Miyasaki KT, et al. Mechanism of extracellular release of human neutrophil calprotectin complex. J Leukoc Biol 2001 70 : 130 4.
19. Rammes A, Roth J, Goebeler M, et al. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997 272 : 9496 502.
20. Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003 98 : 1309 14.
21. Parsi MA, Shen B, Achkar JP, et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology 2004 126 : 1280 6.
22. Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 2001 7 : 460 5.
23. Fine KD, Ogunji F, George J, et al. Utility of a rapid fecal latex agglutination test detecting the neutrophil protein, lactoferrin, for diagnosing inflammatory causes of chronic diarrhea. Am J Gastroenterol 1998 93 : 1300 5.
24. Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002 123 : 450 60.
25. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000 47 : 506 13.
26. Kristinsson J, Armbruster CH, Ugstad M, et al. Fecal excretion of calprotectin in colorectal cancer: Relationship to tumor characteristics. Scand J Gastroenterol 2001 36 : 202 7.
27. Kronborg O, Ugstad M, Fuglerud P, et al. Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 2000 46 : 795 800.
28. Limburg PJ, Ahlquist DA, Sandborn WJ, et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 2000 95 : 2831 7.
29. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: A predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004 39 : 1017 20.
30. Saitoh O, Sugi K, Matsuse R, et al. The forms and the levels of fecal PMN-elastase in patients with colorectal diseases. Am J Gastroenterol 1995 90 : 388 93.
31. Andus T, Gross V, Caesar I, et al. PMN-elastase in assessment of patients with inflammatory bowel disease. Dig Dis Sci 1993 38 : 1638 44.
32. Adeyemi EO, Hodgson HJ. Faecal elastase reflects disease activity in active ulcerative colitis. Scand J Gastroenterol 1992 27 : 139 42.
33. Sugi K, Saitoh O, Hirata I, et al. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: Comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996 91 : 927 34.
34. Silberer H, Kueppers B, Mickisch O, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndome. Clin Lab 2005 51 : 117 26.
35. D'Incà R, Dal Ponte E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007 4 : 429 37.
36. Langhorst J, Elsenbruch S, Müller T, et al. Comparison of four neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 2005 12 : 1085 91.
37. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999 45 (Suppl 2 II43 7.
38. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987 317 : 1625 9.
39. Daperno M, D'Haens G, van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: The SES-CD. Gastrointest Endosc 2004 60 : 505 12.
40. Ajaj W, Lauenstein TC, Langhorst J, et al. Small bowel hydro-MR imaging for optimized ileocecal distension in Crohn's disease: Should an additional rectal enema filling be performed? J Magn Reson Imaging 2005 22 : 92 100.
41. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial. BMJ 1989 298 : 82 6.
42. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976 70 : 439 44.
43. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005 54 : 364 8.
44. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005 353 : 1912 25.
45. Sandborn W, Feagan B, Radford-Schmith G, et al. CDP571, a humanised monoclonal antibody to tumor necrose factor alpha, for moderate to severe Crohn's disease: A randomised, double blind, placebo controlled trial. Gut 2004 53 : 1485 93.
46. Nielsen OH, Vainer B, Madsen SM, et al. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol 2000 95 : 359 67.
47. Brignola C, Lanfranchi GA, Campieri M, et al. Importance of laboratory parameters in the evaluation of Crohn's disease activity. J Clin Gastroenterol 1986 8 : 245 8.
48. Fischbach W, Becker W. Clinical relevance of activity parameters in Crohn's disease estimated by the faecal excretion of 111In-labeled granulocytes. Digestion 1991 50 : 149 52.
49. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. Gut 1994 35 : 231 5.
50. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Cirulation 2003 107 : 671 4.
51. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut 2001 48 : 526 35.